{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:35:31Z","timestamp":1762875331903},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.endonu.2010.03.017","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T14:01:39Z","timestamp":1274968899000},"page":"245-250","source":"Crossref","is-referenced-by-count":14,"title":["Efectos del tratamiento con \u00e1cido zoledr\u00f3nico en pacientes adultos con osteog\u00e9nesis imperfecta"],"prefix":"10.1016","volume":"57","author":[{"given":"Isabel","family":"Pav\u00f3n de Paz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Iglesias Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Dur\u00e1n Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juani","family":"Olivar Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Guijarro De Armas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio","family":"Parra Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endonu.2010.03.017_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJM198408093110606","article-title":"Heritable diseases of collagen","volume":"311","author":"Prockop","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.017_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0065-3101(24)00183-X","article-title":"Osteogenesis imperfecta: compresive management","volume":"35","author":"Marini","year":"1988","journal-title":"Adv Pediatr"},{"key":"10.1016\/j.endonu.2010.03.017_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1297-319X(01)00256-1","article-title":"Osteogenesis imperfecta: lifelong management is imperative and feasible","volume":"68","author":"Chevrel","year":"2001","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.endonu.2010.03.017_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effect of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3 year randomized placebo controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2010.03.017_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","article-title":"The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta","volume":"72","author":"Shapiro","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endonu.2010.03.017_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous noredronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2010.03.017_bib7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1359\/JBMR.050312","article-title":"Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2010.03.017_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"10.1016\/j.endonu.2010.03.017_bib9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Ciclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.017_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1067\/mpd.2003.137","article-title":"Treatment of sintomatic pediatric osteoporosis with ciclic single day intravenous pamidronate infusi\u00f3n","volume":"142","author":"Steelman","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.endonu.2010.03.017_bib11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.arcped.2009.03.008","article-title":"Bisphosphonates and osteogenesis imperfecta in chidren","volume":"16","author":"Gandon-Laloum","year":"2009","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.endonu.2010.03.017_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1056\/NEJM200202283460902","article-title":"Bisphosphonates and osteoporosis","volume":"346","author":"Solomon","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.017_bib13","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal bisphosphonates. From pamidronate disodium to zoledronic acid","volume":"45","author":"Widdler","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.endonu.2010.03.017_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.017_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1517\/14656566.3.7.1007","article-title":"Zolendronate once-yearly increases bone mineral density-implications for osteoporosis","volume":"3","author":"Doggrell","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.endonu.2010.03.017_bib16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risendronate in theprevention and treatment of glucocorticoid induced osteoporosis (HORIZON): a multicentre, double blind double dummy, randomisd, controlled trial","volume":"376","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2010.03.017_bib17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00277-006-0136-y","article-title":"Intravenous zoledronic acid treatment in talasemia-induced osteoporosis: results of a phase II clinical trial","volume":"85","author":"Otrock","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.endonu.2010.03.017_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00002512-200320030-00002","article-title":"Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer","volume":"20","author":"Smith","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.endonu.2010.03.017_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/JPEM.2009.22.1.55","article-title":"Saffety and efficacy of intravenous zoledronic acid in paediatric osteoporosis","volume":"22","author":"Brown","year":"2009","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.endonu.2010.03.017_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s00774-009-0149-4","article-title":"Response to zoledronic acid in children with type III osteogenesis imperfecta","author":"Panigrahi","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.endonu.2010.03.017_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","article-title":"Bisphosphonate associated adverse events","volume":"8","author":"Papapetrou","year":"2009","journal-title":"Hormones (Athens)"}],"container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092210000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092210000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T02:32:19Z","timestamp":1711506739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1575092210000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1575092210000847"],"URL":"https:\/\/doi.org\/10.1016\/j.endonu.2010.03.017","relation":{},"ISSN":["1575-0922"],"issn-type":[{"value":"1575-0922","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}